Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Latest Information Update: 04 Nov 2022
Price :
$35 *
At a glance
- Drugs Tafluprost/timolol (Primary) ; Bimatoprost; Latanoprost; Tafluprost; Travoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 27 Oct 2022 Status changed from recruiting to completed.
- 07 Oct 2021 Planned End Date changed from 31 Dec 2021 to 31 Aug 2022.
- 07 Oct 2021 Planned primary completion date changed from 31 Dec 2021 to 31 Aug 2022.